XL-888
- Generic Name
- XL-888
- Drug Type
- Small Molecule
- Chemical Formula
- C29H37N5O3
- CAS Number
- 1149705-71-4
- Unique Ingredient Identifier
- 7M346920EV
- Background
XL888 has been used in trials studying the treatment of Cancer and Melanoma.
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
- Conditions
- Stage IVB Colorectal CancerStage IVB Pancreatic CancerUnresectable Pancreatic CarcinomaColorectal AdenocarcinomaMetastatic Pancreatic AdenocarcinomaRecurrent Colorectal CarcinomaRecurrent Pancreatic CarcinomaStage III Colorectal CancerStage III Pancreatic CancerStage IIIA Colorectal Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2017-03-30
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 49
- Registration Number
- NCT03095781
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
- Conditions
- MelanomaSkin Cancer
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2025-05-22
- Target Recruit Count
- 26
- Registration Number
- NCT02721459
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2023-01-19
- Target Recruit Count
- 21
- Registration Number
- NCT01657591
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 33
- Registration Number
- NCT00796484
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.